Company Overview - Grace Therapeutics, Inc. is a late-stage biopharma company focused on developing GTx-104, a novel injectable formulation of nimodipine for IV infusion targeting aneurysmal subarachnoid hemorrhage (aSAH) [1][7] - The company has received Orphan Drug Designation from the FDA for its lead clinical assets, providing seven years of marketing exclusivity post-launch in the U.S. and has over 40 granted and pending patents [7] Product Details - GTx-104 is designed to address significant unmet medical needs in aSAH patients, facilitating a convenient IV delivery method that may eliminate the need for nasogastric tube administration [5][6] - The product has been administered to over 150 healthy volunteers, showing good tolerance and significantly lower pharmacokinetic variability compared to oral nimodipine [6] Market Context - Aneurysmal subarachnoid hemorrhage accounts for approximately 5% of all strokes, with an estimated 42,500 patients treated in U.S. hospitals annually [4] - The BIO International Convention, where the CEO will participate, is the largest biotechnology event globally, attracting over 20,000 leaders from various sectors including biopharma and investment [2]
Grace Therapeutics to Participate in the 2025 BIO International Conference